TABLE 3

Causal prophylaxis activity of KAI407 in an in vivo rodent malaria model using P. berghei

CompoundDosea (mg/kg)Survival (%)Prepatent periodb (days ± SD)
Vehicle (untreated)05.75 ± 0.46
Atovaquone2.5100NAd
KAI407c2006.5 ± 0.53
KAI407c100100NAd
  • a A single dose was administered via oral gavage 1–2 h prior to P. berghei sporozoite infection.

  • b Average number of days before blood-stage parasitemia was detected by microscopy.

  • c Formulated in 0.5% (wt/vol) methylcellulose, 0.1% (vol/vol) Tween 80.

  • d NA, not applicable; 100% prophylaxis achieved.